VIVA 2019: New Paclitaxel Data Shows Consistent Mortality Signal, No Clear Cause
Executive Summary
Research investigating outcomes in patients treated with paclitaxel-coated devices demonstrated a consistent if modest mortality signal when compared to bare-metal stents. However, the signal was not seen in real-world data, and some researchers question whether the signal might stem from problems in the original trials.
You may also be interested in...
FDA-Guided Study Finds No Paclitaxel Death Risk In Medicare Patients
The SAFE-PAD study, which looked at data from more than 168,000 Medicare beneficiaries, found a slightly lower death rate in patients treated with drug-coated balloons and stents than those who were not.
Study Links Paclitaxel To Lower-Leg Amputations
New research links the use of stents and balloons coated with the drug paclitaxel to an increased risk of lower-leg amputation shortly following surgery. The study was conducted by Greek researcher Konstantinos Katsanos, who previously found an increased mortality risk in paclitaxel-treated patients.
R&D Roundup, November 2019: LimFlow Starts Pivotal Trial Of Peripheral Shunt; Conservative Coronary Treatment Matches Intervention In Trial
An overview of November’s 10 most-read Medtech Insight articles on topics related to research and development of new medical technology.